急诊药师参与卒中救治团队对急性缺血性卒中门-针时间及患者结局的影响
该单中心回顾性队列纳入2016年8月至2020年5月急诊就诊并接受静脉阿替普酶的缺血性卒中患者164例,其中31例有急诊药师床旁参与(EMP组)、133例无(No EMP组)。EMP组中位门-针时间35分钟(IQR 29-44)显著短于No EMP组42分钟(IQR 34-55),p=0.003;30分钟内溶栓比例35.5% vs 16.5%(p=0.018),45分钟内溶栓比例80.7% vs 57.1%(p=0.015)。出院时NIHSS评分EMP组2分(IQR 0-5)低于No EMP组4分(IQR 0-8.25),p=0.049;在MRI确诊卒中的患者中未观察到次要结局差异。作者认为急诊药师参与卒中救治团队有改善患者照护的潜力。
要点
- 有急诊药师床旁参与时中位门-针时间35分钟(IQR 29-44),无药师时42分钟(IQR 34-55),p=0.003。
- 30分钟内完成溶栓的比例:有药师组35.5% vs 无药师组16.5%,p=0.018。
- 45分钟内完成溶栓的比例:有药师组80.7% vs 无药师组57.1%,p=0.015。
- 出院时NIHSS评分有药师组2分(IQR 0-5)低于无药师组4分(IQR 0-8.25),p=0.049。
- 在MRI确诊卒中的患者中,次要结局未观察到差异。
适用人群与场景
- 2016年8月至2020年5月期间因缺血性卒中表现就诊于急诊并随后接受静脉阿替普酶的患者。
- 排除拒绝阿替普酶或在院外已接受阿替普酶后转院的患者。
研究设计与关键结果
- 单中心回顾性队列研究,共纳入164例患者,其中有急诊药师床旁参与(EMP组)31例,无急诊药师参与(No EMP组)133例。
- 主要结局中位门-针时间:EMP组35分钟(IQR 29-44)vs No EMP组42分钟(IQR 34-55),p=0.003。
- 30分钟内完成门-针时间的病例比例:EMP组35.5% vs No EMP组16.5%,p=0.018。
- 45分钟内接受阿替普酶的病例比例:EMP组80.7% vs No EMP组57.1%,p=0.015。
- 出院时NIHSS评分:EMP组2分(IQR 0-5)vs No EMP组4分(IQR 0-8.25),p=0.049。
- 在MRI确诊卒中的患者中,次要结局未观察到差异。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,急诊药师作为卒中救治团队成员有改善患者照护的潜力。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Time is a critical metric in the emergency department (ED) for acute ischemic stroke and thrombolytic therapy. National guidelines have emphasized tracking time from stroke onset to treatment and decreasing door to needle (DTN) time [1, 2]. Multidisciplinary teamwork is encouraged but, there is limited evidence demonstrating the value of the pharmacist on the stroke response team. The goal of this study is to compare DTN times in the ED with or without a pharmacist at bedside and examine the impact on subsequent patient outcomes.
METHODS: This was a single-center retrospective cohort study. Investigators identified patients who presented to the ED between August 2016 - May 2020 with signs of ischemic stroke and subsequently received intravenous alteplase. Patients were excluded if they refused alteplase or received alteplase off-campus before being transferred. Pharmacist documentation of clinical interventions was used to identify participation on the stroke response team. The primary outcome was median DTN time. Secondary outcomes included severity of deficits measured by the National Institutes of Health Stroke Scale (NIHSS), hospital length of stay (LOS), 90-day Modified Rankin Scale (mRS), incidence of intracranial hemorrhage (ICH), and inpatient all-cause mortality.
RESULTS: Of the 164 patients included, 31 had an emergency medicine pharmacist at bedside (EMP group) and 133 did not (No EMP group). The median DTN time was significantly shorter at 35 min EMP [interquartile range (IQR) 29-44] vs 42 min No EMP [IQR 34-55]; p = 0.003. The number of cases achieving a DTN time of 30 min or less was significantly higher when a pharmacist was involved (35.5% vs.16.5%; p = 0.018) as well as the number of patients receiving alteplase within 45 min (80.7% vs. 57.1%; p = 0.015). NIHSS scores at discharge were lower in the EMP group (2 [IQR 0-5] vs. 4 [IQR 0-8.25]; p = 0.049). In patients with magnetic resonance imaging (MRI) confirmed stroke, a difference was not observed in the secondary outcomes.
CONCLUSION: Patients with an emergency medicine pharmacist as part of their stroke response team had significantly lower DTN times. A higher proportion of these cases met benchmark DTN times less than 45 min and 30 min. An emergency medicine pharmacist on a stroke response team has the potential to improve patient care.
参考来源
- Barbour J, Hushen P, Newman GC, et al. Impact of an emergency medicine pharmacist on door to needle alteplase time and patient outcomes in acute ischemic stroke. Am J Emerg Med. 2021. PMID: 34823191. doi:10.1016/j.ajem.2021.11.015
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。